- Home
- ISRL vs ENTA Comparison
ISRL vs ENTA Comparison
Compare ISRL & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- ENTA
- Stock Information
- Founded
- ISRL 2021
- ENTA 1995
- Country
- ISRL United States
- ENTA United States
- Employees
- ISRL N/A
- ENTA N/A
- Industry
- ISRL Blank Checks
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- ISRL Finance
- ENTA Health Care
- Exchange
- ISRL Nasdaq
- ENTA Nasdaq
- Market Cap
- ISRL 146.3M
- ENTA 152.3M
- IPO Year
- ISRL 2023
- ENTA 2013
- Fundamental
- Price
- ISRL $11.40
- ENTA $8.13
- Analyst Decision
- ISRL
- ENTA Buy
- Analyst Count
- ISRL 0
- ENTA 4
- Target Price
- ISRL N/A
- ENTA $17.25
- AVG Volume (30 Days)
- ISRL 1.1K
- ENTA 485.1K
- Earning Date
- ISRL 01-01-0001
- ENTA 02-10-2025
- Dividend Yield
- ISRL N/A
- ENTA N/A
- EPS Growth
- ISRL N/A
- ENTA N/A
- EPS
- ISRL 0.26
- ENTA N/A
- Revenue
- ISRL N/A
- ENTA $66,590,999.00
- Revenue This Year
- ISRL N/A
- ENTA N/A
- Revenue Next Year
- ISRL N/A
- ENTA N/A
- P/E Ratio
- ISRL $43.68
- ENTA N/A
- Revenue Growth
- ISRL N/A
- ENTA N/A
- 52 Week Low
- ISRL $10.73
- ENTA $4.71
- 52 Week High
- ISRL $11.58
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- ISRL 50.09
- ENTA 77.82
- Support Level
- ISRL $11.43
- ENTA $6.92
- Resistance Level
- ISRL $11.58
- ENTA $8.76
- Average True Range (ATR)
- ISRL 0.00
- ENTA 0.60
- MACD
- ISRL -0.01
- ENTA 0.42
- Stochastic Oscillator
- ISRL 40.00
- ENTA 93.05
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.